Abstract: The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention pertains to a pharmaceutical product comprising a polyclonal immunoglobulin solution in a pre-filled polymer syringe in secondary packaging comprising an oxygen scavenger.

Abstract: The invention relates to a method for the purification of immunoglobulin and/or albumin from a sample of plasma, the method comprising mixing a sample of plasma with a medium chain fatty acid, and recovering the soluble immunoglobulin from the mixture.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.

Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

Abstract: The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 ?mol/l.

Abstract: The present invention relates to the use of proline for reducing the viscosity of a protein preparation.

Abstract: The invention relates to a process for enriching IgA (and IgM) from IgA-comprising material. In particular, it relates to a sequential elution process of an anion exchanger that leads to an advantageous enrichment and separation of monomeric and dimeric IgA.

Abstract: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.

Abstract: The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.